Syndax Pharmaceuticals Inc., a clinical stage biophamaceutical company that is developing therapeutics for cancer, has filed for an initial public offering of its common stock. The Waltham, Massachusetts-based company, which is developing an anti-cancer drug called entinostat, is offering 4.40 million shares of its common stock in the offering.